Johnson & Johnson vs Pfizer Inc.
JNJ vs PFE — side-by-side comparison from reported financials. JNJ leads 10, PFE leads 1 of 11 comparable metrics.
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
Pfizer Inc.
PFE · Healthcare
$28.27+1.62%Mixed
| Metric | JNJ | PFE |
|---|---|---|
| Price | $261.79 | $28.27 |
| Market cap | $631B | $161B |
| Revenue (TTM) | $97.9B | $63.7B |
| Revenue growth | +5.6% | -14.8% |
| Net margin | 21.5% | 6.8% |
| Free cash flow | $22.2B | $11.0B |
| Net cash (debt) | ($27.8B) | ($51.6B) |
| 1-year price return | +37.0% | +12.0% |
| P/E | 29.9 | 37.2 |
| P/E vs own history (cheap-side %) | 16% | 4% |
| Dividend yield | 2.00% | 6.07% |
| Return on equity | 26% | 5% |
| Altman Z-score | — | 1.96 |
| CV checks passed | 10 of 11 | 9 of 11 |
| Employees | 140,800 | 75,000 |
Full résumé-style profiles: JNJ CV · PFE CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.